XBIO REPORT

Tag: mental-health

October 7, 2026

A New Horizon: How the Schizophrenia Treatment Landscape is Evolving (2026-2036)

The Future of Schizophrenia Care The landscape for treating schizophrenia is poised for a significant transformation over the next decade. According to a recent report by DelveInsight, the market is expected to gain substantial momentum between 2026 and 2036, driven by an influx of innovative therapeutic options designed to better manage the complexities of the…

Announcements

DelveInsight, Long-Acting Therapies, mental-health, Pharmaceutical Market, pr-newswire, Schizophrenia
September 30, 2026

New Hope for Social Anxiety: Promising Results from VistaGen’s Phase 3 PALISADE-4 Study

NASDAQ: $VTGN A Breakthrough in Social Anxiety Treatment For millions living with Social Anxiety Disorder (SAD), finding effective relief can be a long and challenging journey. Recent clinical updates from VistaGen offer a glimmer of optimism. The company has announced preliminary positive data from the open-label extension portion of its Phase 3 PALISADE-4 study, evaluating…

Clinical Trial

$VTGN, clinical trials, Fasedienol, mental-health, PALISADE-4, Social Anxiety Disorder, VistaGen
December 25, 2024

Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.

NASDAQ: $AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…

Clinical Trial, Conferences

$AVXL, alzheimers, alzheimers-disease, artificial-intelligence, clinical trials, clinical-research, healthcare, mental-health, neurology, phase-iii, press-releases

Tag: mental-health

A New Horizon: How the Schizophrenia Treatment Landscape is Evolving (2026-2036)

New Hope for Social Anxiety: Promising Results from VistaGen’s Phase 3 PALISADE-4 Study

Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.